TrialSage Study Design Summary - study_design_2024_phase2
Indication
Obesity
Phase
Phase 2
Recommended Primary Endpoint
BMI reduction >=5% at 24 weeks
Historical Success Rate
62%
Recommended Sample Size
250 per arm
Dropout Risk
Moderate (18%)
Regulatory Precedent
EMA-approved in 3 obesity trials since 2022
Top Matched Trials
NCT01234567 - Success - 300 patients - BMI reduction
NCT02345678 - Failed - 150 patients - Weight loss %
NCT03456789 - Success - 260 patients - BMI + quality of life